Clinical Trial Update: A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) [Phase 3]

View source ↗

Summary

BRIM 3 is a Phase 3 trial comparing vemurafenib with dacarbazine in patients with previously untreated metastatic melanoma; results from the study have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2011-11-16